Intracranial aneurysms (IAs) typically develop throughout life, necessitating vigilance in those at high risk in order to avoid aneurysmal subarachnoid hemorrhage (aSAH), the deadly complication of IA. A family history of IA increases personal risk of IA development and rupture: the odds ratio (OR) of subarachnoid hemorrhage (SAH) in persons with one first-degree relative (FDR) is 2.15 while the OR of those with 2 affected FDRs increases to 51.0.
Intracranial aneurysms (IAs) typically develop throughout life, necessitating vigilance in those at high risk in order to avoid aneurysmal subarachnoid hemorrhage (aSAH), the deadly complication of IA. A family history of IA increases personal risk of IA development and rupture: the odds ratio (OR) of subarachnoid hemorrhage (SAH) in persons with one first-degree relative (FDR) is 2.15 while the OR of those with 2 affected FDRs increases to 51.0. 1 In patients with 2 affected FDRs (typically the definition of "familial" IA), it is cost-effective to repeatedly screen for development of de novo aneurysms, with an optimal screening interval of 7 years. 2 A prior decision-analytic model based on prospective, observational data from the Netherlands in the mid-1990s found that screening family members with only one affected FDR extended life of the screenee by less than a month at the cost of 19 years of increased disability, due to treatment complications. 3 Thus, screening of such patients was not advisable, a caution that persists today. 4 However, based on lack of information at the time, this model assumed that patients with negative IA screens had no risk of subsequent aSAH.
In this issue of Neurology ® , Rasing et al. 5 test that assumption by conducting a follow-up study of the original Netherlands cohort 3 of 626 asymptomatic FDRs of 160 patients with aSAH. The relatives (screenees) were screened for IAs with magnetic resonance angiograms (MRAs) from 1995 to 1997. Authors excluded the 25 FDRs (4%) in whom an IA was found. To determine subsequent rates of aSAH, the authors consulted national records; in deceased screenees, they determined cause of death from either the patient's general practitioner or the national register. Those still alive were sent questionnaires. If the questionnaire revealed a history of stroke, their medical data, including imaging, were reviewed. Family members provided information on subsequent aSAH or death in nonresponders. Rates of expected aSAH were determined by applying the age-and sex-specific incident rates of aSAH for the general population 6 to the cohort. The authors found an outcome in 95% of their original 601 screenees with a mean follow-up time of 14.9 years.
There were 3 episodes of aSAH (1 fatal and 2 nonfatal with the following IA sizes and locations: 3 mm, anterior communicating artery; 7 mm, posterior inferior cerebellar artery; 3 mm, basilar artery). They also found one asymptomatic IA in the middle cerebral artery. The 3 episodes of aSAH occurred in 3 different families, at 12 to 15 years after initial negative screening. Of note, rereview of the original screening MRAs revealed the aSAH was from de novo IAs in at least 2 of the 3 cases; the third original MRA did not include the posterior inferior cerebellar artery where the new aneurysm was found. The observed incidence of aSAH in previously screened FDRs of patients with aSAH was 33.6 per 100,000 person-years, compared with 20.0 per 100,000 in the age-and sex-matched general population, an OR of 1.7 (95% confidence interval 0.3-5.7) and a cumulative incidence 15 years after negative screening of 0.50%. This study is important for the general neurologist and neurosurgeon because it re-emphasizes that FDRs are at increased risk of harboring and developing IA and aSAH, even with only one diagnosed relative. It also challenges prior assumptions by providing evidence that a negative screening study for IA in FDRs does not preclude subsequent development of IA and aSAH, even up to 15 years later. The study has notable strengths, including the excellent rate of case ascertainment (95%), 15-year follow-up period, and the sound methodology of determining aSAH rates. However, it leaves many questions unanswered.
First, 3 patients in the original negatively screened cohort developed SAH and one an asymptomatic IA. Because patients were not systematically rescreened, undoubtedly there are additional previously screened individuals who now harbor a de novo, unruptured IA. It would now be valuable to try to rescreen as many of the original cohort as possible to determine the true incidence of de novo asymptomatic IA, which is likely even higher than the reported aSAH risk.
Second, this study does not tell us which family members are at highest risk of aSAH. Of the 2 screenees who had aSAH and had available risk factor information, one was hypertensive and both were smokers.
It is well accepted that these risk factors increase risk of IA development and rupture. 7 Despite a lack of trial data to guide preventive interventions, it is reasonable to counsel strongly for smoking cessation and hypertension treatment in all FDRs of patients with aSAH.
Most important, this study leaves open the question of whether screening FDRs of affected patients will ultimately reduce disability and mortality and be cost-effective. The answer to this hinges on the risks of asymptomatic IA treatment in the current era, particularly regarding new endovascular flow-diversion devices. Although there are numerous published case series of outcomes after endovascular treatments of unruptured IA, we await more definitive outcomes data from randomized trials. 8 Although this study cannot give guidance regarding appropriateness of screening FDRs, it clearly changes the calculus on familial risk of IA and teaches us to remain vigilant in high-risk patients regardless of screening status. Neurologists and neurosurgeons caring for families with aneurysm should carefully consider this new information.
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